Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 341

1.

Pneumococcal responses are similar in Papua New Guinean children aged 3-5 years vaccinated in infancy with pneumococcal polysaccharide vaccine with or without prior pneumococcal conjugate vaccine, or without pneumococcal vaccination.

van den Biggelaar AHJ, Richmond PC, Fuery A, Anderson D, Opa C, Saleu G, Lai M, Francis JP, Alpers MP, Pomat WS, Lehmann D.

PLoS One. 2017 Oct 13;12(10):e0185877. doi: 10.1371/journal.pone.0185877. eCollection 2017.

2.

A Neolithic expansion, but strong genetic structure, in the independent history of New Guinea.

Bergström A, Oppenheimer SJ, Mentzer AJ, Auckland K, Robson K, Attenborough R, Alpers MP, Koki G, Pomat W, Siba P, Xue Y, Sandhu MS, Tyler-Smith C.

Science. 2017 Sep 15;357(6356):1160-1163. doi: 10.1126/science.aan3842.

3.

Serological evidence for transmission of multiple dengue virus serotypes in Papua New Guinea and West Papua prior to 1963.

Luang-Suarkia D, Ernst T, Alpers MP, Garruto R, Smith D, Imrie A.

PLoS Negl Trop Dis. 2017 Apr 24;11(4):e0005488. doi: 10.1371/journal.pntd.0005488. eCollection 2017 Apr.

4.

Cultural factors that affected the spatial and temporal epidemiology of kuru.

Whitfield JT, Pako WH, Collinge J, Alpers MP.

R Soc Open Sci. 2017 Jan 11;4(1):160789. doi: 10.1098/rsos.160789. eCollection 2017 Jan.

5.

A naturally occurring variant of the human prion protein completely prevents prion disease.

Asante EA, Smidak M, Grimshaw A, Houghton R, Tomlinson A, Jeelani A, Jakubcova T, Hamdan S, Richard-Londt A, Linehan JM, Brandner S, Alpers M, Whitfield J, Mead S, Wadsworth JD, Collinge J.

Nature. 2015 Jun 25;522(7557):478-81. doi: 10.1038/nature14510. Epub 2015 Jun 10.

6.

Reflections on pneumonia in the tropics.

Alpers MP.

Pneumonia (Nathan). 2014 Dec 1;4:1-7. doi: 10.15172/pneu.2014.4/416. eCollection 2014. Review.

7.

Adolf Saweri: a tribute.

Alpers MP.

P N G Med J. 2014 Mar-Dec;57(1-4):114-6. No abstract available.

PMID:
26930900
8.

Safety and immunogenicity of neonatal pneumococcal conjugate vaccination in Papua New Guinean children: a randomised controlled trial.

Pomat WS, van den Biggelaar AH, Phuanukoonnon S, Francis J, Jacoby P, Siba PM, Alpers MP, Reeder JC, Holt PG, Richmond PC, Lehmann D; Neonatal Pneumococcal Conjugate Vaccine Trial Study Team.

PLoS One. 2013;8(2):e56698. doi: 10.1371/journal.pone.0056698. Epub 2013 Feb 22.

9.

Genome-wide association study in multiple human prion diseases suggests genetic risk factors additional to PRNP.

Mead S, Uphill J, Beck J, Poulter M, Campbell T, Lowe J, Adamson G, Hummerich H, Klopp N, Rückert IM, Wichmann HE, Azazi D, Plagnol V, Pako WH, Whitfield J, Alpers MP, Whittaker J, Balding DJ, Zerr I, Kretzschmar H, Collinge J.

Hum Mol Genet. 2012 Apr 15;21(8):1897-906. doi: 10.1093/hmg/ddr607. Epub 2011 Dec 30.

10.

Reduction in acute filariasis morbidity during a mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea.

Tisch DJ, Alexander ND, Kiniboro B, Dagoro H, Siba PM, Bockarie MJ, Alpers MP, Kazura JW.

PLoS Negl Trop Dis. 2011 Jul;5(7):e1241. doi: 10.1371/journal.pntd.0001241. Epub 2011 Jul 12.

11.

Some general factors to be considered when implementing a program to control pneumonia.

Alpers MP.

P N G Med J. 2010 Sep-Dec;53(3-4):94-8. No abstract available.

PMID:
23163178
12.

Vaccines against malaria: perspectives from Papua New Guinea.

Mueller I, Genton B, Betuela I, Alpers MP.

Hum Vaccin. 2010 Jan;6(1):17-20. Epub 2010 Jan 15. Review.

PMID:
20173407
13.

A novel protective prion protein variant that colocalizes with kuru exposure.

Mead S, Whitfield J, Poulter M, Shah P, Uphill J, Campbell T, Al-Dujaily H, Hummerich H, Beck J, Mein CA, Verzilli C, Whittaker J, Alpers MP, Collinge J.

N Engl J Med. 2009 Nov 19;361(21):2056-65. doi: 10.1056/NEJMoa0809716.

14.

Three different Plasmodium species show similar patterns of clinical tolerance of malaria infection.

Müller I, Genton B, Rare L, Kiniboro B, Kastens W, Zimmerman P, Kazura J, Alpers M, Smith TA.

Malar J. 2009 Jul 14;8:158. doi: 10.1186/1475-2875-8-158.

15.

The acute phase response in children with mild and severe malaria in Papua New Guinea.

O'Donnell A, Fowkes FJ, Allen SJ, Imrie H, Alpers MP, Weatherall DJ, Day KP.

Trans R Soc Trop Med Hyg. 2009 Jul;103(7):679-86. doi: 10.1016/j.trstmh.2009.03.023. Epub 2009 May 5.

PMID:
19409589
16.

Treatment-seeking behaviour among the Nasioi people of Bougainville: choosing between traditional and western medicine.

Macfarlane JE, Alpers MP.

Ethn Health. 2009 Apr;14(2):147-68. doi: 10.1080/13557850802546588.

PMID:
19280444
17.

HECTD2 is associated with susceptibility to mouse and human prion disease.

Lloyd SE, Maytham EG, Pota H, Grizenkova J, Molou E, Uphill J, Hummerich H, Whitfield J, Alpers MP, Mead S, Collinge J.

PLoS Genet. 2009 Feb;5(2):e1000383. doi: 10.1371/journal.pgen.1000383. Epub 2009 Feb 13.

18.

Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study.

Mead S, Poulter M, Uphill J, Beck J, Whitfield J, Webb TE, Campbell T, Adamson G, Deriziotis P, Tabrizi SJ, Hummerich H, Verzilli C, Alpers MP, Whittaker JC, Collinge J.

Lancet Neurol. 2009 Jan;8(1):57-66. doi: 10.1016/S1474-4422(08)70265-5.

19.

Genetic susceptibility, evolution and the kuru epidemic.

Mead S, Whitfield J, Poulter M, Shah P, Uphill J, Beck J, Campbell T, Al-Dujaily H, Hummerich H, Alpers MP, Collinge J.

Philos Trans R Soc Lond B Biol Sci. 2008 Nov 27;363(1510):3741-6. doi: 10.1098/rstb.2008.0087.

20.

A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New Guinea.

Collinge J, Whitfield J, McKintosh E, Frosh A, Mead S, Hill AF, Brandner S, Thomas D, Alpers MP.

Philos Trans R Soc Lond B Biol Sci. 2008 Nov 27;363(1510):3725-39. doi: 10.1098/rstb.2008.0068.

21.

Mortuary rites of the South Fore and kuru.

Whitfield JT, Pako WH, Collinge J, Alpers MP.

Philos Trans R Soc Lond B Biol Sci. 2008 Nov 27;363(1510):3721-4. doi: 10.1098/rstb.2008.0074.

22.

Review. The epidemiology of kuru: monitoring the epidemic from its peak to its end.

Alpers MP.

Philos Trans R Soc Lond B Biol Sci. 2008 Nov 27;363(1510):3707-13. doi: 10.1098/rstb.2008.0071. Review.

23.

Some tributes to research colleagues and other contributors to our knowledge about kuru.

Alpers MP.

Philos Trans R Soc Lond B Biol Sci. 2008 Nov 27;363(1510):3614-7. doi: 10.1098/rstb.2008.4000. No abstract available.

24.

Reminiscences and reflections on kuru, personal and scientific.

Collinge J, Alpers MP.

Philos Trans R Soc Lond B Biol Sci. 2008 Nov 27;363(1510):3613. doi: 10.1098/rstb.2008.0098. No abstract available.

25.

The relationship between undernutrition and humoral immune status in children with pneumonia in Papua New Guinea.

Cripps AW, Otczyk DC, Barker J, Lehmann D, Alpers MP.

P N G Med J. 2008 Sep-Dec;51(3-4):120-30.

PMID:
21061943
26.

A memorial tribute to Helena Vrbova.

Alpers MP.

P N G Med J. 2008 Sep-Dec;51(3-4):73-9. No abstract available.

PMID:
21061937
27.

Introduction.

Collinge J, Alpers MP.

Philos Trans R Soc Lond B Biol Sci. 2008 Nov 27;363(1510):3607-12. doi: 10.1098/rstb.2008.0103. No abstract available.

28.

Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New Guinea.

Genton B, D'Acremont V, Rare L, Baea K, Reeder JC, Alpers MP, Müller I.

PLoS Med. 2008 Jun 17;5(6):e127. doi: 10.1371/journal.pmed.0050127.

29.

Increased microerythrocyte count in homozygous alpha(+)-thalassaemia contributes to protection against severe malarial anaemia.

Fowkes FJ, Allen SJ, Allen A, Alpers MP, Weatherall DJ, Day KP.

PLoS Med. 2008 Mar 18;5(3):e56. doi: 10.1371/journal.pmed.0050056.

30.

Mass drug administration trial to eliminate lymphatic filariasis in Papua New Guinea: changes in microfilaremia, filarial antigen, and Bm14 antibody after cessation.

Tisch DJ, Bockarie MJ, Dimber Z, Kiniboro B, Tarongka N, Hazlett FE, Kastens W, Alpers MP, Kazura JW.

Am J Trop Med Hyg. 2008 Feb;78(2):289-93.

31.

Daylight rejection with a new receiver for potassium resonance temperature lidars.

Fricke-Begemann C, Alpers M, Höffner J.

Opt Lett. 2002 Nov 1;27(21):1932-4.

PMID:
18033406
32.

Chlamydia trachomatis infection and distribution of serovars in the Eastern Highlands Province, Papua New Guinea.

Suarkia DL, Mgone CS, Lehmann D, Passey ME, Lupiwa T, Paniu MM, Kono J, Kakazo M, Yeka W, Alpers MP.

P N G Med J. 2007 Sep-Dec;50(3-4):134-44.

PMID:
19583096
33.

A history of kuru.

Alpers MP.

P N G Med J. 2007 Mar-Jun;50(1-2):10-9.

PMID:
19354007
34.

Efficacy of single-dose diethylcarbamazine compared with diethylcarbamazine combined with albendazole against Wuchereria bancrofti infection in Papua New Guinea.

Bockarie MJ, Tavul L, Ibam I, Kastens W, Hazlett F, Tisch DJ, Alpers MP, Kazura JW.

Am J Trop Med Hyg. 2007 Jan;76(1):62-6.

PMID:
17255231
35.

Ribotyping of Salmonella enterica serovar Typhi isolates from Papua New Guinea over the period 1977 to 1996.

Combs BG, Passey M, Michael A, Pang T, Lightfoot D, Alpers MP.

P N G Med J. 2005 Sep-Dec;48(3-4):158-67.

PMID:
17212062
36.

Parasitological and clinical efficacy of standard treatment regimens against Plasmodium falciparum, P. vivax and P. malariae in Papua New Guinea.

Genton B, Baea K, Lorry K, Ginny M, Wines B, Alpers MP.

P N G Med J. 2005 Sep-Dec;48(3-4):141-50.

PMID:
17212060
37.

Rifampicin/Cotrimoxazole/Isoniazid versus mefloquine or quinine + sulfadoxine- pyrimethamine for malaria: a randomized trial.

Genton B, Mueller I, Betuela I, Casey G, Ginny M, Alpers MP, Reeder JC.

PLoS Clin Trials. 2006 Dec 22;1(8):e38.

38.

Small-area variations in the epidemiology of malaria in Madang Province. 1986.

Cattani JA, Moir JS, Gibson FD, Ginny M, Paino J, Davidson W, Alpers MP.

P N G Med J. 2005 Mar-Jun;48(1-2):95-101. No abstract available.

PMID:
16894841
39.

The first 50 years of the Papua New Guinea Medical Journal: a celebration of its golden jubilee.

Alpers MP.

P N G Med J. 2005 Mar-Jun;48(1-2):2-26. No abstract available.

PMID:
16894833
40.

Antenatal care in Goroka: issues and perceptions.

Larsen GL, Lupiwa S, Kave HP, Gillieatt S, Alpers MP.

P N G Med J. 2004 Sep-Dec;47(3-4):202-14.

PMID:
16862944
41.

Kuru in the 21st century--an acquired human prion disease with very long incubation periods.

Collinge J, Whitfield J, McKintosh E, Beck J, Mead S, Thomas DJ, Alpers MP.

Lancet. 2006 Jun 24;367(9528):2068-74.

PMID:
16798390
42.

Effect of the malaria vaccine Combination B on merozoite surface antigen 2 diversity.

Flück C, Schöpflin S, Smith T, Genton B, Alpers MP, Beck HP, Felger I.

Infect Genet Evol. 2007 Jan;7(1):44-51. Epub 2006 May 2.

PMID:
16647307
43.

The epidemiology of kuru in the period 1987 to 1995.

Alpers MP; Kuru Surveillance Team.

Commun Dis Intell Q Rep. 2005;29(4):391-9.

44.

Hospital twinning between Australia and Papua New Guinea.

Alpers MP.

P N G Med J. 2003 Mar-Jun;46(1-2):81-6.

PMID:
16450786
45.

Variant Creutzfeldt-Jakob disease: implications for the health care system.

Dunstan RA, Alpers MP.

Aust N Z J Public Health. 2005 Aug;29(4):308-12. Review.

PMID:
16222925
46.

Benefits of routine immunizations on childhood survival in Tari, Southern Highlands Province, Papua New Guinea.

Lehmann D, Vail J, Firth MJ, de Klerk NH, Alpers MP.

Int J Epidemiol. 2005 Feb;34(1):138-48. Epub 2004 Nov 23.

PMID:
15561755
47.

Strain-specific humoral response to a polymorphic malaria vaccine.

Flück C, Smith T, Beck HP, Irion A, Betuela I, Alpers MP, Anders R, Saul A, Genton B, Felger I.

Infect Immun. 2004 Nov;72(11):6300-5.

48.

Polymerase chain reaction diagnosis and the changing pattern of vector ecology and malaria transmission dynamics in papua new Guinea.

Benet A, Mai A, Bockarie F, Lagog M, Zimmerman P, Alpers MP, Reeder JC, Bockarie MJ.

Am J Trop Med Hyg. 2004 Sep;71(3):277-84.

PMID:
15381806
49.

Disposition of artesunate and dihydroartemisinin after administration of artesunate suppositories in children from Papua New Guinea with uncomplicated malaria.

Karunajeewa HA, Ilett KF, Dufall K, Kemiki A, Bockarie M, Alpers MP, Barrett PH, Vicini P, Davis TM.

Antimicrob Agents Chemother. 2004 Aug;48(8):2966-72.

50.

Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children.

Genton B, Al-Yaman F, Betuela I, Anders RF, Saul A, Baea K, Mellombo M, Taraika J, Brown GV, Pye D, Irving DO, Felger I, Beck HP, Smith TA, Alpers MP.

Vaccine. 2003 Dec 8;22(1):30-41.

PMID:
14604568

Supplemental Content

Loading ...
Support Center